Amphastar Pharmaceuticals (AMPH) Barclays 28th Annual Global Healthcare Conference summary

Key business and product performance

• BAQSIMI and Primatene MIST drove growth, with BAQSIMI up 12% and Primatene MIST up 7% year-over-year.

• BAQSIMI's U.S. business remains strong, with international presence shrinking as the company exits unprofitable markets, raising U.S. mix to 85% by year-end.

• Glucagon experienced a sharp decline due to new competition and market shift to ready-to-use products, impacting margins.

• Primatene MIST is expected to achieve low double-digit growth in 2026, supported by a 5% price increase and new marketing initiatives.

• Epinephrine prefilled syringe segment faces tailwinds as the company is now the sole supplier, while multi-dose vials still face headwinds.

Strategic vision and business model

• Operates a fully integrated, vertically aligned business model with in-house R&D, manufacturing, and marketing capabilities, ensuring quality and compliance across all stages.

• Employs a dual-strategy growth model focused on both pipeline development and strategic acquisitions to diversify and expand its product portfolio.

• Emphasizes high quality, efficiency, and technology, resulting in strong net income margins and consistent revenue growth from 2018 to 2025.

Pipeline and future growth

• Ipratropium (AMP-007) approved with early Q2 launch planned, expected to be a top growth driver with 180 days of exclusivity.

• AMP-018 and insulin product AMP-004 targeted for 2027 launches, with AMP-004 seen as the larger opportunity due to market size and manufacturing readiness.

• By 2026, proprietary and biosimilar products are projected to comprise 85% of the pipeline, up from 37% in 2021, reflecting a strategic shift away from generics.

• Expansion of branded and proprietary pipeline is a strategic focus, including in-licensed oncology and ophthalmology assets.

• Proprietary pipeline includes innovative peptides, biosimilars, and complex generics, with several products in late-stage development or recently launched.